// App-Quantinova.ai

SAT0243 (2018) : Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programmes

Researchers

Presenter

  • P.J. Mease

Principal Investigators

  • J. Kremer

  • S. Cohen

  • J.R. Curtis

  • C. Charles-Schoeman

  • E.V. Loftus

  • J. Greenberg

  • N. Palmetto

  • K. S. Kanik

  • D. Graham

  • C. Wang

  • P. Biswas

  • G. Chan

  • R. DeMasi

  • H. Valdez

  • T. Hendrikx

  • T. V. Jones

Medical Centers

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

  • Albany Medical College and The Center for Rheumatology, Albany, NY

  • Metroplex Clinical Research Center, Dallas, TX,

  • University of Alabama at Birmingham, Birmingham, AL

  • University of Southern California, Los Angeles, CA

  • Mayo Clinic, Rochester, MN

  • Corrona LLC, Southborough, MA

  • Pfizer Inc, New York, NY

  • Pfizer Inc, Groton

  • Pfizer Inc., Collegeville, United States

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Musculoskeletal

  • Pulmonary/Respiratory Diseases

  • Dermatology

Disease

  • Rheumatoid arthritis

  • Deep vein thrombosis

  • Psoriatic arthritis

  • Ulcerative colitis

  • Pulmonary embolism

  • Venous thrombosis

  • Inflammatory Arthritis

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Methotrexate

  • Tasocitinib

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved